FDA to Hear Sept. 17 Testimony on Low-Dose Testosterone for Menopausal Women
Updated
Updated · UCHealth Today · Sep 10
FDA to Hear Sept. 17 Testimony on Low-Dose Testosterone for Menopausal Women
2 articles · Updated · UCHealth Today · Sep 10
Summary
Sept. 17 is the date of an FDA meeting where Dr. Margaret Wierman and other scientists will discuss research needs and possible low-dose testosterone drug development for menopausal women.
Wierman said evidence supports only one established use in postmenopausal women—hypoactive sexual desire disorder—and even then studies show a modest gain of about one additional satisfying sexual episode per month.
She said there are no data proving testosterone improves cognition, bone, muscle or overall wellness in menopausal women, and warned higher levels may raise risks including acne, infertility-like effects and possibly breast cancer through conversion to estradiol.
Her broader message on testosterone was similarly cautious: men generally should receive TRT only after two morning tests show levels below 300 ng/dL plus symptoms, because unnecessary use can worsen sleep apnea, thicken blood and reduce fertility.